Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A42994 | 32869840 | Clin Infect Dis | Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. | 2021 | Details |
| A42995 | 32865242 | Hepatology | Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations. | 2021 | Details |
| A42996 | 32864357 | World J Transplant | Links between donor macrosteatosis, interleukin-33 and complement after liver transplantation. | 2020 | Details |
| A42997 | 32860090 | Dig Dis Sci | Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. | 2020 | Details |
| A42998 | 32858662 | Eur J Gastroenterol Hepatol | Association between nonalcoholic fatty liver disease and portal vein thrombosis: a systematic review and meta-analysis. | 2020 | Details |
| A42999 | 32853777 | Ann Hepatol | For fatty liver diseases, it is time to utilize non-invasive fibrosis tests to predict liver related events rather than just histological stages of hepatic fibrosis! | 2020 | Details |
| A43000 | 32852813 | Aliment Pharmacol Ther | Editorial: pregnancy and the gastroenterologist. | 2020 | Details |
| A43001 | 32850201 | Cureus | Glycogenic Hepatopathy: A Reversible Complication of Uncontrolled Diabetes Mellitus. | 2020 | Details |
| A43002 | 32845785 | J Interferon Cytokine Res | Key Players of Hepatic Fibrosis. | 2020 | Details |
| A43003 | 32841331 | J Anim Sci | Increase of E3 ubiquitin ligase NEDD4 expression leads to degradation of its target proteins PTEN/IGF1R during the formation of goose fatty liver. | 2020 | Details |
| A43004 | 32832515 | Hepatobiliary Surg Nutr | The socioeconomic aspects of nonalcoholic fatty liver disease: food insecurity as a novel risk factor for steatosis and liver fibrosis. | 2020 | Details |
| A43005 | 32832510 | Hepatobiliary Surg Nutr | Probiotics and synbiotics targeting the intestinal microbiome attenuate non-alcoholic fatty liver disease. | 2020 | Details |
| A43006 | 32832507 | Hepatobiliary Surg Nutr | Nonalcoholic fatty liver disease and type 2 diabetes: a burgeoning problem with unclear solutions. | 2020 | Details |
| A43007 | 32832501 | Hepatobiliary Surg Nutr | Nonalcoholic fatty liver disease in type 2 diabetes: awareness is the first step toward change. | 2020 | Details |
| A43008 | 32829627 | J Biol Regul Homeost Agents | Potential influence of miR-192 on the efficacy of saxagliptin treatment in T2DM complicated with non-alcoholic fatty liver disease. | 2021 | Details |
| A43009 | 32821334 | World J Hepatol | Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling. | 2020 | Details |
| A43010 | 32821043 | Med Sci (Paris) | [Role of autophagy in liver sinusoidal endothelial cells in nonalcoholic steatohepatitis]. | 2020 | Details |
| A43011 | 32819754 | J Hepatol | MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant? | 2020 | Details |
| A43012 | 32814360 | J Diabetes Investig | In search of the optimal management strategy for non-alcoholic fatty liver disease in type 2 diabetes patients. | 2020 | Details |
| A43013 | 32814313 | Dig Dis | Validity of International Classification of Diseases, Tenth Revision, Codes for Cirrhosis. | 2020 | Details |
| A43014 | 32812927 | Metabol Open | Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients. | 2020 | Details |
| A43015 | 32812686 | FASEB J | GPR91, a critical signaling mechanism in modulating pathophysiologic processes in chronic illnesses. | 2020 | Details |
| A43016 | 32807574 | J Hepatol | From mice to humans: Unravelling the genetic levers of NASH. | 2020 | Details |
| A43017 | 32805206 | Lancet Gastroenterol Hepatol | Intestinal motility: a therapeutic target for NAFLD? | 2020 | Details |
| A43018 | 32800588 | J Hepatol | Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice. | 2020 | Details |
| A43019 | 32797344 | Dig Dis Sci | NAFLD and Statins. | 2020 | Details |
| A43020 | 32795138 | J Am Coll Nutr | Vitamin D and Wellbeing beyond Infections: COVID-19 and Future Pandemics. | 2020 | Details |
| A43021 | 32795106 | Metab Syndr Relat Disord | Metabolic Syndrome in Children and Adolescents: Is There a Universally Accepted Definition? Does it Matter? | 2020 | Details |
| A43022 | 32794597 | Hepatology | Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome-Coronavirus 2 Pandemic. | 2020 | Details |
| A43023 | 32781957 | Mini Rev Med Chem | Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents. | 2020 | Details |
| A43024 | 32781719 | Biomolecules | Not So Slim Anymore-Evidence for the Role of SUMO in the Regulation of Lipid Metabolism. | 2020 | Details |
| A43025 | 32780879 | Hepatology | Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. | 2021 | Details |
| A43026 | 32778015 | Exp Clin Transplant | Resolution of Severe Graft Steatosis Before Living-Donor Liver Transplant After 86 Pounds of Weight Loss. | 2020 | Details |
| A43027 | 32771359 | Metabolism | Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated steatohepatitis). | 2020 | Details |
| A43028 | 32768596 | Gastroenterology | Epoxygenase-Derived Epoxyeicosatrienoic Acid Mediators Are Associated With Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Fibrosis. | 2020 | Details |
| A43029 | 32767866 | Korean J Radiol | Noninvasive Imaging for the Evaluation of Non-Alcoholic Fatty Liver Disease Spectrum. | 2020 | Details |
| A43030 | 32763241 | Gastroenterology | Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. | 2020 | Details |
| A43031 | 32759301 | Gut | NAFLD between genes and environment: what drives fibrogenesis? | 2020 | Details |
| A43032 | 32758101 | J Am Coll Nutr | Interplay Between Insulin Resistance and Body Fat Mass in Evolution of Perturbations Linked to the Metabolic Syndrome in Non-Diabetics: Emphasis on Inflammatory Factors. | 2020 | Details |
| A43033 | 32757393 | Hepatology | Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights. | 2020 | Details |
| A43034 | 32755308 | Am J Physiol Gastrointest Liver Physiol | Microbiota on biotics: probiotics, prebiotics, and synbiotics to optimize growth and metabolism. | 2020 | Details |
| A43035 | 32751062 | Int J Mol Sci | Consumption of Wild Rice (Zizania latifolia) Prevents Metabolic Associated Fatty Liver Disease through the Modulation of the Gut Microbiota in Mice Model. | 2020 | Details |
| A43036 | 32750452 | Diabetes Metab | Non-alcoholic fatty liver disease and chronic kidney disease: renal benefit with liver stiffness assessment? | 2020 | Details |
| A43037 | 32740920 | Clin Pharmacol Ther | Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis and Cholestatic Liver Diseases: Workshop Report. | 2020 | Details |
| A43038 | 32740703 | Acta Diabetol | Nonalcoholic fatty liver disease and cardiovascular risk in severely obese adolescents. | 2020 | Details |
| A43039 | 32738082 | Liver Int | Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data. | 2020 | Details |
| A43040 | 32730829 | Cell Mol Gastroenterol Hepatol | Acetyl-CoA Carboxylase Inhibition as a Therapeutic Tool in the Battle Against NASH: Hitting More Than Just One Mechanism? | 2020 | Details |
| A43041 | 32727636 | Gene Expr | The Dynamic Interplay Between Mast Cells, Aging/Cellular Senescence, and Liver Disease. | 2020 | Details |
| A43042 | 32725977 | Korean Circ J | Non-alcoholic Fatty Liver Disease, Cardio-metabolic Syndrome and Hypertension: One Concept Fits Multi-systemic Presentations. | 2020 | Details |
| A43043 | 32714511 | Int J Obes Suppl | From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. | 2020 | Details |
| A43044 | 32707055 | Metabolism | Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). | 2020 | Details |
| A43045 | 32702498 | Ann Hepatol | Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis. | 2020 | Details |
| A43046 | 32701591 | Chin Med J (Engl) | From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. | 2020 | Details |
| A43047 | 32697967 | EBioMedicine | Thrombospondin1 as a potential therapeutic target for human nonalcoholic fatty liver disease. | 2020 | Details |
| A43048 | 32697146 | J Urol | Re: The Independent Association of Non-Alcoholic Fatty Liver Disease with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Function Scores. | 2020 | Details |
| A43049 | 32696995 | JPEN J Parenter Enteral Nutr | JPEN Journal Club 57. The Hawthorne Effect. | 2020 | Details |
| A43050 | 32694863 | Nat Metab | Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease. | 2019 | Details |
| A43051 | 32694801 | Nat Metab | Exposing NASH-a disease in stealth mode. | 2019 | Details |
| A43052 | 32694177 | Gut | Diet-refractory NASH in an elderly woman. | 2020 | Details |
| A43053 | 32693115 | J Ethnopharmacol | A review of the processed Polygonum multiflorum (Thunb.) for hepatoprotection: Clinical use, pharmacology and toxicology. | 2020 | Details |
| A43054 | 32692117 | J Clin Gastroenterol | Longitudinal Change in Simple Scores Identifies Fibrosis Status in People With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43055 | 32692037 | Curr Opin Lipidol | Emerging insight into the role of cellular cholesterol in the pathogenesis of nonalcoholic steatohepatitis progression. | 2020 | Details |
| A43056 | 32690662 | Diabetes | A New FGF21 Analog for the Treatment of Fatty Liver Disease. | 2020 | Details |
| A43057 | 32690129 | Gene Expr | Epidemiological Realities of Alcoholic Liver Disease: Global Burden, Research Trends, and Therapeutic Promise. | 2020 | Details |
| A43058 | 32687812 | Am J Med | Cardiometabolic Morbidity in Adults With Cerebral Palsy and Spina Bifida. | 2020 | Details |
| A43059 | 32680469 | BMC Gastroenterol | Plasma Lipidome, PNPLA3 polymorphism and hepatic steatosis in hereditary hemochromatosis. | 2020 | Details |
| A43060 | 32668973 | Am J Chin Med | Gastrodin Pretreatment Protects Liver Against Ischemia-Reperfusion Injury via Activation of the Nrf2/HO-1 Pathway. | 2020 | Details |
| A43061 | 32668489 | J Viral Hepat | Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. | 2020 | Details |
| A43062 | 32656821 | J Appl Toxicol | Zebrafish: An emerging model system to study liver diseases and related drug discovery. | 2020 | Details |
| A43063 | 32652034 | J Nutr | A Low ω-6 to ω-3 PUFA Ratio (n-6:n-3 PUFA) Diet to Treat Fatty Liver Disease in Obese Youth. | 2020 | Details |
| A43064 | 32647638 | Liver Cancer | Reply to the Letter to the Editor: "Comparison of the Safety and Efficacy of Yttrium-90 Radioembolization for Nonalcoholic Fatty Liver Disease-Associated and Hepatitis B Virus-Associated Hepatocellular Carcinoma". | 2020 | Details |
| A43065 | 32647637 | Liver Cancer | Comparison of Safety and Efficacy of Yttrium-90 Radioembolization for Nonalcoholic Fatty Liver Disease-Associated and Hepatitis B Virus-Associated Hepatocellular Carcinoma. | 2020 | Details |
| A43066 | 32646248 | Expert Opin Drug Discov | What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipeline. | 2020 | Details |
| A43069 | 32645512 | Metabolism | Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. | 2020 | Details |
| A43070 | 32643632 | Indian J Dermatol Venereol Leprol | Metabolic syndrome and female gender, but not methotrexate, are the important associations of significant liver fibrosis in patients with moderate-to-severe psoriasis as detected by transient elastography. | 2021 | Details |
| A43071 | 32637065 | Ther Adv Endocrinol Metab | Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. | 2020 | Details |
| A43072 | 32629560 | Zhonghua Jie He He Hu Xi Za Zhi | [Progress in research on obstructive sleep apnea hypopnea syndrome and nonalcoholic fatty liver disease]. | 2020 | Details |
| A43073 | 32626927 | Mol Med Rep | TLR4 mediates inflammation and hepatic fibrosis induced by chronic intermittent hypoxia in rats. | 2020 | Details |
| A43074 | 32624568 | Exp Mol Med | Exercise training modulates the gut microbiota profile and impairs inflammatory signaling pathways in obese children. | 2020 | Details |
| A43075 | 32624396 | J Acad Nutr Diet | Effect of Incorporating Genetic Testing Results into Nutrition Counseling and Care on Health Outcomes: An Evidence Analysis Center Systematic Review-Part II. | 2020 | Details |
| A43076 | 32621204 | Indian J Gastroenterol | Author's reply to comment on review article: Treatment of non-alcoholic fatty liver disease-Current perspectives. | 2020 | Details |
| A43077 | 32617777 | Indian J Gastroenterol | Non-alcoholic fatty liver and cancer. | 2020 | Details |
| A43078 | 32617153 | Clin Liver Dis (Hoboken) | Reproductive Health and Nonalcoholic Fatty Liver Disease in Women: Considerations Across the Reproductive Lifespan. | 2020 | Details |
| A43079 | 32617151 | Clin Liver Dis (Hoboken) | Spotlight on Impactful Research: Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study. | 2020 | Details |
| A43080 | 32615084 | Cell Mol Gastroenterol Hepatol | Nature or Nurture? The Answer Is "Both" in Nonalcoholic Steatohepatitis. | 2020 | Details |
| A43081 | 32614087 | Hepatology | Acyl Coenzyme A Thioesterase 9: A Novel Target for Nonalcoholic Fatty Liver Disease by Shuttling Mitochondrial Short-Chain Fatty Acids? | 2020 | Details |
| A43082 | 32613782 | Diabetes Metab J | Response: Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus (Diabetes Metab J 2020;44:267-76). | 2020 | Details |
| A43083 | 32613780 | Diabetes Metab J | Letter: Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus (Diabetes Metab J 2020;44:267-76). | 2020 | Details |
| A43084 | 32609746 | PLoS One | Correction: Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice. | 2020 | Details |
| A43085 | 32603747 | Physiol Behav | Relative contribution of fat diet and physical inactivity to the development of metabolic syndrome and non-alcoholic fat liver disease in Wistar rats. | 2020 | Details |
| A43086 | 32603059 | Acta Gastroenterol Belg | NASH : a welfare disease with emerging questions and adequate answer attempts. | 2020 | Details |
| A43087 | 32598598 | Ter Arkh | [Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features]. | 2019 | Details |
| A43088 | 32593683 | J Hepatol | Maternal obesity: A severe risk factor in hepatocarcinogenesis? | 2020 | Details |
| A43089 | 32592253 | Aliment Pharmacol Ther | Editorial: PNPLA3 genotype and liver diseases-more than non-alcoholic fatty liver disease. | 2020 | Details |
| A43090 | 32592246 | Aliment Pharmacol Ther | Editorial: PNPLA3 genotype and liver diseases-more than non-alcoholic fatty liver disease. Authors' reply. | 2020 | Details |
| A43091 | 32591859 | Cell Mol Life Sci | KHK inhibition for the treatment of hereditary fructose intolerance and nonalcoholic fatty liver disease: a double-edged sword. | 2020 | Details |
| A43092 | 32590463 | Chin Med J (Engl) | Association of serum zinc-α2-glycoprotein with non-alcoholic fatty liver disease. | 2020 | Details |
| A43093 | 32587620 | Stem Cells Int | Human Adipose Derived Cells in Two- and Three-Dimensional Cultures: Functional Validation of an In Vitro Fat Construct. | 2020 | Details |
| A43094 | 32586106 | Antioxid Redox Signal | Phospholipase D as a Potential Modulator of Metabolic Syndrome: Impact of Functional Foods. | 2020 | Details |
| A43095 | 32585124 | Appl Physiol Nutr Metab | Lipid droplets are both highly oxidized and Plin2-covered in hepatocytes of diet-induced obese mice. | 2020 | Details |